Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more
Biomedical research foundation Novo Nordisk Foundation named Mads Krogsgaard Thomsen, EVP and CSO at Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) as CEO, effective March 1. He replaces Birgitte Nauntofte, who has been the foundation’s CEO since 2009. Filling Thomsen’s shoes at Novo will be Marcus Schindler who is promoted to CSO and EVP of research and early development, and Martin Holst Lange, who is promoted to EVP of development. Schindler was previously SVP and head of global drug discovery, while Lange was SVP of global development. The Novo Nordisk Foundation, through its Novo Holdings subsidiary, is the majority shareholder of Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) and awards about DKK5 billion ($812.5 million) per year in scientific and humanitarian grants.
Ramona Sequeira will become the first woman to chair PhRMA next year after trade group named the Takeda Pharmaceuticals USA Inc. president chair-elect on Wednesday. It also appointed Vas Narasimhan, CEO of Novartis AG (NYSE:NVS; SIX:NOVN), as board treasurer...